The First Trust Alerian Disruptive Technology Real Estate UCITS ETF ("DTRE") is not issued, sponsored, endorsed, sold or promoted by Alerian or its affiliates (collectively, "Alerian"), and Alerian makes no representation or warranty, express or implied, to the purchasers or owners of DTRE or any member of the public regarding the advisability of investing in securities generally or in DTRE particularly or the ability of the Alerian Disruptive Technology Real Estate Index (the "Index") to track general market performance
0.5 s (Asn 402, *P = 0.0201) respectively for single knockouts and 0.6 s (Asn 247/Asn 395, P = 0.0694)
Looking Beyond Surgery Low back pain is the leading cause of disability worldwide, and nearly 80% of adults will experience significant low back pain at some point
Studies show that Semaglutide reduces appetite, improves control of eating, and reduces food cravings in addition to improving glycemic control